Successfully producing large quantities of biotherapeutics, including monoclonal antibodies and recombinant protein products, depends on robust and reliable cell line development (CLD). Issues that ...

Traditional approaches to biologics production—relying on one-size-fits-all expression vectors and empirical process optimization—have led to inefficiencies in expression, scalability, and ...

The Trade-off Between Physiological Authenticity and Experimental Convenience: Navigating the Cellular Foundation of ...

Cell line development continues to face technical and operational hurdles in transfection, clone selection, and media optimization. Manual screening, extended culture timelines, and fragmented data ...

Asimov, the synthetic biology company advancing the design and manufacture of therapeutics, today announced a licensing agreement for its CHO Edge System with RevOpsis Therapeutics ("RevOpsis"), a ...

Cell line creation is a major success factor in biologics manufacturing. It establishes the basis for product yield, quality, and long-term process stability. However, despite significant ...

The development of humans and other animals unfolds gradually over time, with cells taking on specific roles and functions via a process called cell fate determination. The fate of individual cells, ...

The MarketWatch News Department was not involved in the creation of this content. SAN DIEGO, Sept. 15, 2025 /PRNewswire/ -- Abzena, the leading end-to-end integrated CDMO for complex biologics and ...